COMPANY:

BGI Group

"The Institute of Intelligent Medical Research (IIMR) of BGI Genomics, in collaboration with Sweden’s Uppsala University, has published the largest multi-omics study of colorectal cancer (CRC) to date. The study aimed to understand the functional and prognostic impact of cancer-causing somatic mutations, revealing new genetic alterations and developing a new molecular classifier of tumor variants. This research was published in the journal Nature on August 7th, 2024."

"Novazym Laboratory from Poznań and the Polish Medical Institute of the Ministry of Internal Affairs and Administration in Warsaw have started cooperating on a screening study in which the effectiveness of COLOTECT™ 1.0 test is compared with colonoscopy."

"BGI Genomics and the Rwanda Biomedical Centre (RBC) launched a cervical cancer screening program in Ngoma District, Eastern Province, Rwanda. This program will provide 20,000 Human papillomavirus (HPV) DNA tests for local women, aiming to enhance cervical cancer screening and prevention efforts and improve local precision medical testing capabilities."

"...BGI Genomics, signed a Memorandum of Understanding (MoU) with the Saudi Public Health Authority (PHA), in which the two sides further extend their combined efforts based on screening and detection of infectious diseases to all-round cooperation in the fields of reproductive health, early screening of cancer, scientific research projects and talent cultivation, to inject new impetus into the cause of public health in Saudi Arabia."

"On October 2, 2023, BGI Genomics signed a Memorandum of Understanding (MoU) with the Colombian National Cancer Institute (INC or Instituto Nacional de Cancerologia). This collaboration, which aims to foster research and further develop cutting-edge solutions based on genetic sequencing for early diagnosis of cervical and colorectal cancer, reflects a shared dedication to enhancing health outcomes in the region."

"Brunei Darussalam's healthcare landscape achieved another significant feat with the launch of the Borneo Genomics Innovation Sdn Bhd (BGIB) Molecular Testing Lab on August 16, 2023, a state-of-the-art laboratory offering invasive prenatal testing, screening for Down syndrome, detection of human papillomavirus (HPV) and COLOTECT, a non-invasive method of screening for colorectal cancer."

"BGI Almanahil Health for Medical Services, a wholly owned subsidiary of BGI Genomics, and Tibbiyah Holding...announced the establishment of Genalive, an independent clinical laboratory and a joint venture between these two organizations...Genalive combines BGI Genomics' cutting-edge genomic technologies and Tibbiyah's clinical expertise to offer comprehensive genetic testing and precision medicine solutions."

"BGI Genomics is pleased to announce that its proprietary COLOTECT DNA methylation-based test DNA Methylation Detection Kit for Human SDC2, ADHFE1, and PPP2R5C GENES (Real-time PCR) has been listed on the Australian Register of Therapeutic Goods (ARTG) from Australia’s regulatory authority Therapeutic Goods Administration (TGA)."

"Recently, BGI Genomics' COLOTECT™ 1.0 DNA Methylation Detection Kit for Human SDC2, ADHFE1, and PPP2R5C Genes (Real-Time PCR), Sample Pretreatment Kit for Methylation Detection, DNA Isolation Kit, Stool Sample Collection Kit have received market authorization from Malaysia's Medical Device Authority...With this certification, COLOTECT™ 1.0 is now available in over six countries/regions and markets that recognize these certificates."

"The Precision Oncology Center of Universidad Mayor...obtained two cutting-edge sequencers and other equipment due to collaboration with BGI Genomics, allowing for more detailed genetic testing at half the cost and time of existing technologies...With this goal, the Center, in partnership with BGI Genomics, recently acquired two state-of-the-art sequencers that will allow oncologists throughout the country to access unique technology in Chile to improve the treatment of their patients."

"BGI Genomics is pleased to announce the launch of COLOTECT 1.0 in Slovakia, in collaboration with its local partner, Zentya...COLOTECT 1.0 is one of the first-ever fecal DNA tests for colorectal cancer that is available in the country. It is a non-invasive fecal DNA test developed by BGI Genomics for detecting colorectal cancer and precancerous lesions. It uses multiplex methylation-specific PCR (MSP) technology to trace abnormal colorectal cancer DNA-methylation biomarkers from fecal samples."

"Illumina said on Thursday that it has reached a settlement and licensing agreement with China's BGI and its affiliates, including MGI Tech, that will end the multi-year legal battle between the two sequencing firms in the US...The settlement ends all outstanding litigation, including at least four lawsuits in US district courts and four pending appeals in the US Court of Appeals for the Federal Circuit, concerning patent infringement and antitrust allegations."

"BGI announces that its Homologous Recombination Deficiency Detection Kit (Combinatorial Probe-Anchor Synthesis Sequencing Method) has recently obtained CE-IVDD approval...This kit is developed for the qualitative detection of genomic homologous recombination deficiency (HRD) based on high-throughput sequencing technology, and adopts the combinatorial probe-anchor synthesis sequencing method."

"BGI’s DNA Methylation Detection Kit for Human SDC2, ADHFE1 and PPP2R5C Genes (Real-time PCR) obtains the Medical Device Import License of Thailand Food and Drug Administration...The detection kit will bring significant implications for CRC prevention in Thailand and reduce the occurrence of related diseases."

"BGI Genomics announces that its Non-small Cell Lung Cancer Mutation Analysis Software and EGFR/KRAS/ALK Gene Mutation Detection Kit (Combinatorial Probe-Anchor Synthesis Sequencing Method) have been approved by the Saudi Food and Drug Authority (SFDA)...BGI’s mutation analysis software and detection kit offer a comprehensive solution for detecting NSCLC, allowing clinicians to diagnose timely and provide patients with effective treatment options."

"BGI Genomics announces that its DNA Methylation Detection Kit for Human SDC2, ADHFE1, and PPP2R5C Genes (Real-Time PCR) has been certified by the Saudi Food and Drug Authority (SFDA)...The SFDA approval marks BGI’s commitment to the advocacy of cancer screening and early detection in Saudi Arabia and the entire Middle East."

"BGI Genomics Co. LTD...announces that its Lung Cancer Library Reagent - Lung Cancer Circulating Tumor DNA Multi-gene Mutation Combined Detection Kit (Combinatorial Probe-Anchor Synthesis Sequencing Method), and Pan-Cancer Library Reagent - Solid Tumor Multi-gene Combined Detection Kit (Combinatorial Probe-Anchor Synthesis Sequencing Method) have got the CE mark in December 2021."